220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
Authors:
- P.G. AftimosPAP.G. Aftimos
- J. CortésJCJ. Cortés
- F.C. BidardFBF.C. Bidard
- V. KaklamaniVKV. Kaklamani
- A. BardiaABA. Bardia
- P. NevenPNP. Neven
- G. StreichGSG. Streich
- A. MonteroAMA. Montero
- F. ForgetFFF. Forget
- M.A. Mouret ReynierMRM.A. Mouret Reynier
- J. SohnJSJ. Sohn
- D. TaylorDTD. Taylor
- 13 September 2022
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 33 (7) , S638